Home Depot's CEO says the retailer cut its outlook partly due to "the potential impacts to the U.S. consumer arising from recently announced tariffs."Retailread more
For investors still haunted by last week's monster sell-off, the market's comeback is set to last, according to J.P. Morgan's quant guru.Marketsread more
A U.S.-China trade deal would be less likely if President Xi cracks down violently on the large-scale protests in Hong Kong, Secretary of State Mike Pompeo tells CNBC.Politicsread more
The launch follows a "preview" earlier this month that allowed only limited customers to apply.Technologyread more
Financial advisers are always "buying at the wrong time and selling at the wrong time because they're emotional," the billionaire founder of Baron Capital says.Marketsread more
Energy stocks may be fueling up for a comeback rally. One technical analyst says that after the sector's pummeling, these two stocks look particularly good.Trading Nationread more
Bruce Linton says he bought more stock in Canopy Growth — even though the cannabis company he co-founded fired him earlier this summer.Health and Scienceread more
"We think the stock is appealing once again," J.P. Morgan says of Beyond Meat.Marketsread more
A new probe could bring more pressure to some of the nation's largest tech firms, which are already facing federal scrutiny.Technologyread more
Got extra stuff? Got extra space? A new company is ready to make a match. Neighbor is a barely two-year-old company that connects homeowners online with people who need...Real Estateread more
The company confirmed it's hiring a team of veteran journalists to help curate news stories in its soon-to-launch news tab.Technologyread more
This week, investors could get a better picture of how this year's intense flu season is impacting health care firms, with three major health insurers and the nation's largest for-profit hospital operator set to report fourth quarter results.
Here's what to watch:
Hospital operator HCA reports Tuesday. With a large presence in Texas — where the flu outbreak has been especially severe — investors will be watching for the impact on HCA's admissions.
Aetna is also set to report results on Janaury 30th, but the bigger news for its investors this week will be the regulatory outlook for the CVS' proposed $69 billion acquisition of the health insurer.
The 30-day Hart-Scott-Rodino Act anti-trust waiting period on the CVS-Aetna deal expires on February 2nd. If regulators raise no objections to extend the review period, it would lift a big hurdle for the merger.
In regulatory filings, the companies said they expect the merger to be completed in the second half of this year. The deal carries a $2.1 billion break-up fee.
When Anthem reports ahead of the bell Wednesday, analysts will be watching for its outlook on how tax reform will impact 2018 earnings.
Analysts at Cantor Fitzgerald raised their 2018 earnings estimate for the insurer from $13.00 per share to $16.00, based in part on the assumption that Anthem's tax rate will fall from 35.5 percent to 28 percent, due to tax reform.
Whether they'll use that extra cash to pursue a merger is likely to be one of the big questions for New CEO Gail Boudreaux.
"We see the company as having the budget and motivation to guild out a significant AI team both organilcally and through M&A [mergers and acquisitions]," analysts at Piper Jaffray wrote in a recent research note, estimating that Anthem has $5.5 billion in deployable capital, beyond tax savings.
On Thursday, Cigna CEO David Cordani is likely to face questions about how mergers and acquisitions will figure in the firm's plans to deploy tax reform savings.
Leerink analyst Ana Gupte said in a recent research note that Cigna executives aren't likely to pursue acquiring their own pharmacy benefit manager. They also don't seem anxious to do a deal, despite recent moves by competitors.
"Cigna is not looking at a deadline on capital deployment and is still actively contemplating its… strategic priorities," Gupte wrote.